P1. 15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Background: Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the recommended first-line treatment for patients with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations. The role of afatinib after failure of first-genera...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
Elsevier
2018
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/22820/1/JTO%202nd%20afatinib.pdf http://ir.unimas.my/id/eprint/22820/ https://www.jto.org/article/S1556-0864(18)31905-1/fulltext |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|